Researcher.Life Logo

Human Vaccines and Immunotherapeutics : Impact Factor & More

eISSN: 2164-554XpISSN: 2164-5515
JournalOpen Access

Aims and Scope of Human Vaccines and Immunotherapeutics

Human Vaccines & Immunotherapeutics is a monthly peer-reviewed medical journal covering research into vaccines and immunotherapeutics in humans. It was established in 2005 as Human Vaccines, and obtained its current name in 2012. It is published by Taylor & Francis and the editor-in-chief is Ronald Ellis (FutuRx). According to the Journal Citation Reports, the journal had a 2013 impact factor of 3.643. Less

Key Metrics

CiteScore
5.5
H-Index
80
Impact Factor
< 5
Scite Index
0.83 5-Year SI
SJR
Q1Immunology
SNIP
1.36
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Human Vaccines and Immunotherapeutics

Human Vaccines and Immunotherapeutics Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher TAYLOR & FRANCIS INC
Language English
Frequency Monthly
Article Processing ChargesEUR 2895 | GBP 2495 | USD 3175
Publication Time11
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorInternational Society for Vaccines (ISV)
FrequencyMonthly
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 11
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Human Vaccines and Immunotherapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Human Vaccines and Immunotherapeutics

Herpes zoster hospitalization burden in Spain during the initial period of recombinant zoster vaccine implementation
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Determinants of vaccine hesitancy among primary healthcare workers in Türkiye
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Türkiye, 2019–2025: An update in the 10th to 15th years of routine pneumococcal conjugate vaccination
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Mumps disease and vaccination in Africa: A scoping review
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Nursing students’ knowledge and attitudes toward human papillomavirus vaccination and infection
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Vaccination in systemic lupus erythematosus
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Herpes zoster hospitalization burden in Spain during the initial period of recombinant zoster vaccine implementation
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Determinants of vaccine hesitancy among primary healthcare workers in Türkiye
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Türkiye, 2019–2025: An update in the 10th to 15th years of routine pneumococcal conjugate vaccination
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Mumps disease and vaccination in Africa: A scoping review
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Nursing students’ knowledge and attitudes toward human papillomavirus vaccination and infection
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics
Vaccination in systemic lupus erythematosus
  • 31 Dec 2026
  • Human Vaccines & Immunotherapeutics

FAQs on Human Vaccines and Immunotherapeutics